Clinical-stage biotechnology company TME Pharma N.V. (Euronext Growth Paris: ALTME) announced on Monday a strategic plan to externalise and monetise its second clinical-stage asset, NOX-E36, targeting ophthalmic diseases. NOX-E36, an L-stereoisomer RNA aptamer inhibiting the CCL2 chemokine, has shown promising anti-fibrotic effects in preclinical studies by the Singapore Eye Research Institute.
Plans involve creating a separate corporate entity focused on developing NOX-E36 for ophthalmology to attract private investment. Preclinical and clinical data support a rapid transition to Phase 2 clinical trials. NOX-E36 has demonstrated efficacy in preventing fibrosis in glaucoma surgery models and has shown a strong safety and tolerability profile in 175 clinical trial participants.
Fibrosis significantly impacts the treatment of several eye diseases, including diabetic retinopathy, age-related macular degeneration and primary open-angle glaucoma. NOX-E36's anti-fibrotic mode of action positions it as a potential solution for these conditions.
TME Pharma specializes in developing therapies targeting the tumour microenvironment (TME) and cancer immunity cycle. The company's lead candidate, NOX-A12, is being evaluated in Phase 1/2 trials for glioblastoma and other cancers, with promising results observed in combination with radiotherapy and bevacizumab.
NOX-E36's transition to a dedicated ophthalmology-focused entity will enable TME Pharma to leverage its potential in addressing unmet medical needs in eye diseases, furthering its strategy to focus on oncology treatments.
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
NKGen Biotech receives US FDA Fast Track designation for troculeucel in Alzheimer's treatment
Neuphoria Therapeutics to receive USD15m milestone payment from Merck
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Royalty Pharma to invest up to USD250m in Biogen's lupus treatment
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
IXICO's AI platform validated in Huntington's Disease research
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Spinogenix reveals topline results from Phase 2 study in Fragile X syndrome
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval